The Native Antigen Company
The Native Antigen Company introduces 10 new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19. These antibodies recognize different epitopes of the SARS-CoV-2 spike glycoprotein, nine of which are SARS-CoV-2 specific and do not cross-react with other human coronaviruses; they extend our existing range and offer researchers a source of high-quality reagents for R&D of in vitro diagnostics, therapeutics, and vaccines for COVID-19. The SARS-CoV-2 antibodies were raised using our own S1 and S2 recombinant spike proteins as immunogens. Produced using our proprietary mammalian expression system, these antigens exhibit full glycosylation and proper folding to ensure that antibodies raised against them are highly specific. The antibodies have been screened against our other coronavirus proteins, including SARS, MERS, NL63, OC43, 229E, and HKU1, to demonstrate specificity. Three of the antibodies have been shown to be specific for the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cellular angiotensin-converting enzyme 2 (ACE2) receptor.